26 May 1997 Assessment of surface concentrations in resorbable ocular implants: controlled drug delivery devices for 5-fluorouracil (5-FU)
Author Affiliations +
Proceedings Volume 2971, Ophthalmic Technologies VII; (1997) https://doi.org/10.1117/12.275108
Event: BiOS '97, Part of Photonics West, 1997, San Jose, CA, United States
Abstract
The antineoplastic drug 5-fluorouracil (5-fluoro- 2,4,(1H,3H)-pyrimidinedione; 5-FU) has been used to control proliferation of penetrating fibroblasts and to prevent channel closure following glaucoma filtration surgery (trabeculectomy) or laser sclerectomy. Because of the toxicity of the drug, administration of low dosages slowly over time, at the site of the desired treatment, is indicated for optimum efficacy. Repeated injections of low dosages of the drug represent an undesirable intervention and may also result in unwanted toxicity to the corneal epithelium. A suitable biocompatible and resorbable polymer matrix composed of a poly (D,L-lactic-co-glycolic acid: PLGA) has been admixed with varying amounts of 5-FU and cast as shapes suitable for intracorneal implantation. Slow biodegradation of this polymer over a one to two week period has been shown to result in an acceptably slow drug release mechanism. An issue arising during the clinical evaluation of the efficacy of this drug delivery system was how best to quantify the concentration of 5-FU and its distribution spatially in the solid implant. FT-IR and FT-Raman spectroscopies distinguishes between the drug and the polymer matrix and were used to differentiate and quantitate the 5-FU concentration of the implants.
© (1997) COPYRIGHT Society of Photo-Optical Instrumentation Engineers (SPIE). Downloading of the abstract is permitted for personal use only.
Peter J. Milne, Peter J. Milne, Sandrine Gautier, Sandrine Gautier, Jean-Marie A. Parel, Jean-Marie A. Parel, Valerie Jallet, Valerie Jallet, } "Assessment of surface concentrations in resorbable ocular implants: controlled drug delivery devices for 5-fluorouracil (5-FU)", Proc. SPIE 2971, Ophthalmic Technologies VII, (26 May 1997); doi: 10.1117/12.275108; https://doi.org/10.1117/12.275108
PROCEEDINGS
10 PAGES


SHARE
Back to Top